Non-small cell lung cancer

News

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

News

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Chances of FDA approval for Spectrum Pharma's lung cancer candidate poziotinib and Oncopeptides' Pepaxto for multiple myeloma have taken a dive, after the regulator's expert advisors voted

News

Jounce setback casts deeper pall over ICOS as cancer target

A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.

News

Phase 3 trial confirms Lumakras role in lung cancer

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for

News

Strike three for Novartis' canakinumab as lung cancer therap...

Expectations for Novartis' canakinumab as an oncology therapy were already fading fast, and have now been nixed after a third phase 3 trial in non-small cell lung cancer (NSCLC) failed to m

News

Tagrisso paired with Hutchmed drug clears lung cancer test

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations.

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

FDA panel shoots down Spectrum, Oncopeptides' cancer drugs

Jounce setback casts deeper pall over ICOS as cancer target

Phase 3 trial confirms Lumakras role in lung cancer

Strike three for Novartis' canakinumab as lung cancer therap...

Tagrisso paired with Hutchmed drug clears lung cancer test

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks